| Gene symbol | tk |
| GTO ID | GTC0325 |
| Trial ID | NCT02831933 |
| Disease | Lung Non-Squamous Non-Small Cell Carcinoma | Lung Squamous Cell Carcinoma | Uveal Melanoma |
| Altered gene | tk |
| Therapeutic/Target gene | Therapeutic gene |
| Therapy | Gene transfer |
| Treatment | Adv-HSV-tk |
| Co-treatment | Valacyclovir|radiation therapy|nivolumab |
| Phase | Phase2 |
| Recruitment status | Terminated |
| Title | Phase II Window of Opportunity Trial of Stereotactic Body Radiation Therapy and In Situ Gene Therapy Followed by Nivolumab in Metastatic Squamous or Non-Squamous Non-Small Cell Lung Carcinoma and Metastatic Uveal Melanoma |
| Year | 2016 |
| Country | United States |
| Company sponsor | The Methodist Hospital Research Institute |
| Other ID(s) | Pro00014976 |
| Vector information | |||||||||
|
|||||||||
| Cohort 1 | |||||||||||||
|
|||||||||||||